Skip to main content
TXG logo

TXG · 10x Genomics, Inc.

Track TXG — free
$51.80 -5.58 (-9.72%) At close · Nov 20
Market Cap
$6.81B
Shares
131.53M
Volume · Nov 20 3.23M Avg daily vol (3M) 3.36M

Price & Indicators

 

Key stats

Close
$51.80
Fri 20 Nov
Open
$55.77
Fri 20 Nov
Average volume, 30 days
3.2M
shares a session
Short interest
12.5M
9.5% of shares · 4.1 days to cover
Day range
$51.30$56.44
Open $55.77 Close $51.80
52-week closing range
$15.46$97.74
Close $51.80 47.0% under the high
Short volume, last session
34%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 6
Price history
Jan 2020 to Nov 2026

Up next

Feb 11, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows 1% as gross margin rises to 75%

10x Genomics, Inc. reported products and services revenue of $150.2 million for the three months ended September 30, 2026, up 1%, while gross margin rose to 75%. It agreed to acquire Proteintech Genomics, Inc. for $6.1 million.

Revenue $150.67M ▲ 1.1% Net loss $19.43M Diluted EPS -$0.15
Read from the MD&A section
4 source passages
10x Genomics, Inc. Products and services revenue increased $2.2 million, or 1%, to $150.2 million for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025. Gross margin increased to 75% for the three months ended September 30, 2026 as compared to 67% for the three months ended September 30, 2025. On June 8, 2026, we entered into a stock purchase agreement (“SPA”) to acquire 100% of the outstanding shares of common stock of Proteintech Genomics, Inc. (“PTG”), a division of Proteintech Group, Inc. (“Proteintech”), for $6.1 million in cash. Open the document at this passage
Nov 5
Earnings call
Raises 2026 Outlook and ATERRA Shipment Plan to 50

10x Genomics reported third-quarter revenue of $150.7 million, up 1%, raised its 2026 revenue outlook to $625 million to $635 million and expects approximately 50 ATERRA instruments by year-end, up from approximately 40.

4 source passages
Earlier today, 10x Genomics released financial results for the third quarter ended September 30, 2026. Revenue for the third quarter was $150.7 million, representing 1% growth over the prior year period. Turning to our outlook for the rest of the year, we are raising our full-year outlook and now expect 2026 revenue to be in the range of $625 million to $635 million. As a result, we now expect to ship approximately 50 ATERRA instruments by year-end, up from our previous expectation of approximately 40. Open the document at this passage
Nov 5
Current report 8-K
Raises 2026 revenue guidance amid 1% quarterly growth

10x Genomics, Inc. reported third-quarter 2026 revenue of $150.7 million, up 1% year over year, and net loss of $19.4 million; it raised full-year revenue guidance to $625 million to $635 million.

Financial results
4 source passages
10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026. Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025. Net loss was $19.4 million for the third quarter of 2026, as compared to net loss of $27.5 million for the corresponding prior year period. 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $625 million to $635 million, versus the previous range of $610 million to $630 million. Open the document at this passage
Nov 2
Current report 8-K Events of Oct 28
Board appoints Ansuman Satpathy and Joseph Gilliam as Class III directors

10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors effective October 28, 2026. Gilliam was also named Audit Committee Chair on October 30, 2026, with a $25,000 annual retainer.

Director or officer change, or executive pay
2 source passages
On October 28, 2026, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Class III directors effective immediately On October 30, 2026, Mr. Gilliam was appointed Chair of the Audit Committee of the Board of Directors, for which he shall receive an annual retainer of $25,000 (prorated as necessary). Open the document at this passage
Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $151.04M ▼ 12.6% Net loss $17.93M Diluted EPS -$0.14
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$618.58M
Trailing 12 months
Net income (TTM)
−$67.08M
Trailing 12 months
Revenue growth YoY
+1.1%
Year over year
Operating margin
-11.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
1.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.2%
Year over year · more shares
Price change (1Y)
+214.7%
Trailing year
Short interest
9.5%
Latest settlement · 4.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. 10x raised full-year revenue guidance and increased its ATERRA shipment outlook, while gross margin improved, losses narrowed, spatial consumables grew 16%, and ATERRA demand remained strong. Instrument revenue fell sharply, near-term and 2027 gross margins are expected to be lower, and production and installation capacity are expected to constrain ATERRA shipments into next year.

Bullish
  • + Full-year 2026 revenue guidance was raised to $625 million-$635 million from $610 million-$630 million.
  • + The expected ATERRA shipment count increased to approximately 50 instruments by year-end from approximately 40. new
  • + Third-quarter gross margin increased to 75% from 67% in the prior-year period. new
  • + Operating loss and net loss narrowed from the prior-year period. new
Bearish
  • − Total instrument revenue declined 43%, with chromium instrument revenue down 23% and spatial instrument revenue down 57%.
  • − Fourth-quarter gross margin is expected to be in the low-to-mid 60s as ATERRA shipments ramp. new
  • − Gross margin is expected to be lower in 2027 because it will be an instrument-heavy year and consumables will ramp during the year. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg −29%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 44%
mid-range
Momentum
relative strength
Strong
1-month return −28%
trailing
6-month return +69%
trailing
YTD return +218%
this year
Relative strength +78%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $73 › 200d $43 — 50d above 200d
Institutional flow Accumulating
+25% holders QoQ · +155 funds added
Insider flow Distributing
Net -$6.3M over 90 days · 100% sells
Short interest Falling
9.48% of shares out · ▼ -2.0% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
498 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Excellent
Revenue growth +68%
Y/Y
Gross margin 181%
contracting
EPS growth +77%
Y/Y
Free cash flow $130.1M
Quant / Vol
risk profile
Very High
Volatility 77%
annualized · 1-yr
Max drawdown −47%
past year
ATR 11.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 6
Latest guidance · from the Earnings Call filed Nov 5, 2026
2026 revenue · full year 2026 Raised $625M – $635M
Aug 6, 2026 $610M – $630M changed to Nov 5, 2026 $625M – $635M
prior FY $642.82M midpoint −2.0% Y/Y
Guided vs delivered · last 6 settled
Revenue fourth quarter 2025
guided $154M – $158M
$166.03M Beat +6.4%
Revenue third quarter 2025
guided $140M – $144M
$149M Beat +4.9%
Revenue full year 2024
guided $640M – $660M
$610.79M Miss −6.0%
Revenue full year 2023
guided $610M – $625M
$618.73M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
−29% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
44% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $73 › 200d $43 — 50d above 200d
Institutional flow Accumulating
+25% holders QoQ · +155 funds added
Insider flow Distributing
Net -$6.3M over 90 days · 100% sells
Short interest Falling
9.48% of shares out · ▼ -2.0% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
498 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $52 · 44% Range high $98
vs 200-day avg +19% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Gross margin 75% the third quarter of 2026 —
Total consumables revenue 134.33M Three Months Ended September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TXG
10x Genomics, Inc.
this stock
$6.81B +217.6% +68.1% — 9.5%
ABT
Abbott Laboratories
$178.39B -17.8% +5.7% 38.4 1.1%
MDT
Medtronic plc
$127.84B +4.0% +8.4% 24.6 1.8%
SYK
Stryker Corp
$118.01B -11.8% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$60.85B -56.0% +12.5% 17.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
498
% held
99.0%
Net QoQ
+1.8M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
332
View
Short & Settlement
Short Interest Falling
Shares short
12.5M
Days to cover
4.1d
Change
-259.1K sh
View
Short Volume
Short vol %
34%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
22
Value
$1.6K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
48.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$6.3M
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$642.8M
Net income (FY)
$-43.5M
EPS diluted
$-0.35
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 6, 2026
This year
14

10x Genomics, Inc. reported products and services revenue of $150.2 million for the three months ended September 30, 2026, up 1%, while gross margin rose to 75%. It agreed to acquire Proteintech Genomics, Inc. for $6.1 million.

View
Proposed Sales
Value
$223.1K
Shares
4.0K
Filed
Nov 20, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
10x Genomics Expands Global Resea…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
TXG -11.0% -27.6% +68.7% -26.1% +217.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -2.4% -18.4% +77.9% -17.4% +216.4%
Key facts CIK 1770787 CUSIP 88025U109 13F (30d) 482 filings 441 filers Visit website Investor relations